Article

Asembia 2022 Summit to Address Biosimilar Adoption, Policy Implications for Specialty Pharmacy

Author(s):

Numerous topics will be addressed at this year's Asembia Specialty Pharmacy Summit, held in-person in Las Vegas from May 2 through 5, including updates on cell and gene therapies and insights on the future of the industry.

Asembia’s 2022 Specialty Pharmacy Summit is scheduled to take place next week from May 2-5 in Las Vegas, Nevada, and will feature keynote speaker Scott Gottlieb, MD, former commissioner of the FDA and senior advisor at CMS.

Sessions and panels will include discussions on all things specialty pharmacy, including advancements in treatment therapies, market access strategies, and the pharmaceutical pipeline.

The organization’s last meeting was held in October 2021, postponed due to COVID-19, while next week’s gathering will see a return to the regular Spring timeslot.

Continuing education courses run the gamut of treatments for disease states, including opportunities to learn about managing atopic dermatitis in pediatric patients and a review for specialty pharmacists on management of idiopathic pulmonary fibrosis.

Featured sessions also include updates on popular topics such as the role of pharmacists in driving future biosimilar adoption and the importance of protecting patient data alongside the risks to national data security.

Policy discussions will focus on challenges navigating state regulations, a look at President Biden’s health agenda in an election year, and the passage of the 30-year anniversary of the Public Health Service (PHS) 340B program.

On the payer side, experts are slated to discuss the slow uptake of digital therapeutics while representatives from Amazon Pharmacy and Eli Lilly will present a session called “Bringing Ecommerce Insights to Pharmacy.”

Updates on cell and gene therapies will be provided along with legal considerations on specialty pharmacies engaging in different patient infusion models.

The agenda features several patient-centered discussions including one on overcoming social determinates of health via specialized teams, presented by representatives from Walgreens.

An additional session titled “Navigating the Pandemic With EUA Therapies,” will address issues raised by supply challenges, therapy indications and time constraints, while “Understanding the Use of Patient-Reported Outcomes in Improving Pharmacy Care,” will highlight CVS’ efforts to optimize its supply management practices through personalized digital engagement.

Pharmacy accreditation, shifts in sites of care, and value based contracting will also be discussed, along with insights on medication adherence and financial barriers that my lead to prescription abandonment.

The conference will take place at the Wynn & Encore hotel with over 5000 industry attendees expected at the in-person event.

Keep an eye on our Asembia conference page for live coverage from Las Vegas, starting May 2.

Related Videos
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo